Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus SEMGLEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus SEMGLEE.
HUMALOG MIX 75/25 vs SEMGLEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin lispro (25%) and intermediate-acting insulin lispro protamine suspension (75%). Insulin lispro lowers blood glucose by binding to insulin receptors, facilitating cellular glucose uptake, inhibiting hepatic gluconeogenesis, and promoting glycogenesis and lipogenesis.
Long-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake (especially in skeletal muscle and fat) and inhibiting hepatic glucose production via binding to insulin receptors, activating the insulin receptor tyrosine kinase cascade.
Subcutaneous injection: 75% insulin lispro protamine suspension and 25% insulin lispro solution. Dose individualized based on glycemic goals and prior insulin regimen. Typical total daily dose: 0.5-1 unit/kg/day divided into two doses (pre-breakfast and pre-dinner).
Subcutaneous injection, 0.2 units/kg/day initially, adjusted based on blood glucose levels. Typical maintenance dose: 0.5-1 unit/kg/day.
None Documented
None Documented
Insulin lispro: 0.5-1 hour; protamine-bound fraction prolongs absorption, resulting in a biphasic profile with an effective half-life of 2-4 hours for the 75% NPL component.
18.3 hours; reflects protracted absorption from subcutaneous depot, enabling once-daily dosing
Renal: 60-80% as unchanged drug following subcutaneous absorption; the remaining fraction undergoes hepatic metabolism and biliary/fecal excretion.
Renal (30-80% as intact insulin); fecal (negligible)
Category C
Category C
Insulin Analog
Insulin Analog